Welcome to our dedicated page for Harrow Health SEC filings (Ticker: HROWM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HROWM represents Harrow, Inc. 11.875% Senior Notes due 2027, listed on The Nasdaq Stock Market LLC. This SEC filings page focuses on regulatory documents that reference these senior notes and their issuer, Harrow, Inc., which operates in the pharmaceutical preparations sector. Filings such as Forms 8-K, 10-K, and 10-Q for Harrow, Inc. provide the primary source of information for understanding the context in which the HROWM notes exist.
In a reported Form 8-K, Harrow, Inc. disclosed a change in its independent registered public accounting firm. The company’s audit committee dismissed Crowe LLP and approved Deloitte & Touche LLP as the new independent registered public accounting firm, subject to completion of Deloitte’s standard client acceptance procedures and an engagement letter. The filing notes that Crowe’s report on the company’s financial statements for a referenced year did not include an adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope, or accounting principles. It also states that there were no disagreements or reportable events within the meaning of Item 304 of Regulation S-K during Crowe’s engagement.
Using this page for HROWM analysis
Through this page, users can review Harrow, Inc.’s SEC filings that relate to its capital structure, financial reporting, and auditor relationships, all of which are relevant when assessing the HROWM senior notes. Real-time updates from EDGAR and AI-powered summaries help explain the key points in filings such as 8-Ks, annual reports on Form 10-K, quarterly reports on Form 10-Q, and other documents that may reference the HROWM notes or the company’s broader debt and equity securities.
Harrow, Inc. filed a Form 3 for Chief Commercial Officer Patrick William Sullivan, reporting a stock option over 30,000 shares of common stock. The option has an exercise price of $39 per share and expires on September 1, 2035.
According to the vesting schedule, 25% of the option shares vest on the one-year anniversary of the grant date. The remaining shares vest in 12 equal quarterly installments over the following three years, becoming fully vested and exercisable on September 1, 2029. The option is held directly.
Harrow, Inc. filed a Form 3 for Chief Commercial Officer Patrick William Sullivan, reporting a stock option over 30,000 shares of common stock. The option has an exercise price of $39 per share and expires on September 1, 2035.
According to the vesting schedule, 25% of the option shares vest on the one-year anniversary of the grant date. The remaining shares vest in 12 equal quarterly installments over the following three years, becoming fully vested and exercisable on September 1, 2029. The option is held directly.
Harrow, Inc. filed an update covering its outlook and leadership team. The company reaffirmed its full-year 2025 revenue guidance in a range of $270 million to $280 million, signaling no change to its previously communicated expectations.
Harrow also appointed Patrick W. Sullivan as Chief Commercial Officer, effective January 30, 2026. He brings more than 25 years of commercial leadership experience from roles at Corium Therapeutics, AstraZeneca, Shire, Adolor, Novartis, and Bayer. Under his offer letter, Sullivan will receive a $425,000 annual base salary, a target annual bonus equal to 40% of base compensation, and 40,000 restricted stock units. Of these, 25,000 RSUs vest if Harrow’s revenue reaches $230,000,000 in a calendar quarterly period, and 15,000 RSUs vest three years from the award date.
Harrow, Inc. filed an update covering its outlook and leadership team. The company reaffirmed its full-year 2025 revenue guidance in a range of $270 million to $280 million, signaling no change to its previously communicated expectations.
Harrow also appointed Patrick W. Sullivan as Chief Commercial Officer, effective January 30, 2026. He brings more than 25 years of commercial leadership experience from roles at Corium Therapeutics, AstraZeneca, Shire, Adolor, Novartis, and Bayer. Under his offer letter, Sullivan will receive a $425,000 annual base salary, a target annual bonus equal to 40% of base compensation, and 40,000 restricted stock units. Of these, 25,000 RSUs vest if Harrow’s revenue reaches $230,000,000 in a calendar quarterly period, and 15,000 RSUs vest three years from the award date.
Harrow, Inc. notified that its Audit Committee dismissed Crowe LLP as the company's independent registered public accounting firm, effective immediately, and engaged Deloitte to serve as the new independent registered public accounting firm to audit the consolidated financial statements for the year ending December 31, 2025. The engagement with Deloitte was communicated on September 17, 2025 and is subject to Deloitte's standard client acceptance procedures and execution of an engagement letter. The filing references a letter from Crowe LLP dated September 19, 2025, and an Inline XBRL cover page file as exhibits. The disclosure does not state the reasons for the change or provide audit opinions or financial impacts.